Israel biotech seeks investment
This article was originally published in Clinica
Executive Summary
If $3-4 billion of public and private funds were invested in the Israeli biotechnology sector, sales would be boosted to somewhere in the region of $4 billion within 5-7 years. This is the view put forward by Professor Haim Aviv at a meeting of the board of governors of the Israel-US Binationational and Industrial Research Foundation (BIRD). He said that currently Israel's 160 biotech companies make aggregate sales in the region of $800 million, but that the sector had enjoyed phenomenal growth over the past decade. Further growth was, however, being hampered by lack of financial resources and managerial skill, Professor Aviv said.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.